GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » CVS Health Corp (NYSE:CVS) » Definitions » Sloan Ratio %
中文

CVS Health (CVS Health) Sloan Ratio %

: 6.33% (As of Dec. 2023)
View and export this data going back to 1952. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

CVS Health's Sloan Ratio for the quarter that ended in Dec. 2023 was 6.33%.

As of Dec. 2023, CVS Health has a Sloan Ratio of 6.33%, indicating the company is in the safe zone and there is no funny business with accruals.


CVS Health Sloan Ratio % Historical Data

The historical data trend for CVS Health's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVS Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 -1.37 -2.15 -2.99 6.33

CVS Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.99 -1.83 0.90 5.69 6.33

Competitive Comparison

For the Healthcare Plans subindustry, CVS Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVS Health Sloan Ratio % Distribution

For the Healthcare Plans industry and Healthcare sector, CVS Health's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where CVS Health's Sloan Ratio % falls into.



CVS Health Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

CVS Health's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(8344-13426
--20889)/249728
=6.33%

CVS Health's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(8344-13426
--20889)/249728
=6.33%

CVS Health's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 2136 (Mar. 2023 ) + 1901 (Jun. 2023 ) + 2261 (Sep. 2023 ) + 2046 (Dec. 2023 ) = $8,344 Mil.
CVS Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 7438 (Mar. 2023 ) + 5908 (Jun. 2023 ) + 2716 (Sep. 2023 ) + -2636 (Dec. 2023 ) = $13,426 Mil.
CVS Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -8514 (Mar. 2023 ) + -10362 (Jun. 2023 ) + -771 (Sep. 2023 ) + -1242 (Dec. 2023 ) = $-20,889 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CVS Health  (NYSE:CVS) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, CVS Health has a Sloan Ratio of 6.33%, indicating the company is in the safe zone and there is no funny business with accruals.


CVS Health Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of CVS Health's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


CVS Health (CVS Health) Business Description

Address
One CVS Drive, Woonsocket, RI, USA, 02895
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the U.S. CVS is also the largest pharmacy benefit manager (acquired through Caremark), processing over 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Executives
Edward J Ludwig director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Michael F Mahoney director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Thomas F. Cowhey officer: SVP, Interim CFO 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
J Scott Kirby director 233 S. WACKER DRIVE 11TH FL WHQLD, CHICAGO IL 60606
Brian A Kane officer: EVP/President, Aetna 500 W MAIN STREET, LOUISVILLE KY 40202
James David Clark officer: SVP, Cont & Chief Acct Officer ONE CVS DRIVE, WOONSOCKET RI 02760
Karen S Lynch officer: EVP & Pres, Aetna Bus Unit 151 FARMINGTON AVENUE, RW61, HARTFORD CT 06156
Samrat S. Khichi officer: EVP, CPO and General Counsel C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas M Moriarty officer: EVP & General Counsel 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey R. Balser director 3657 RICHLAND AVE., NASHVILLE TN 37205
Alan Lotvin officer: EVP, Transformation 55 NOD ROAD, AVON CT 06001
Daniel P Finke officer: EVP/Pres, Health Care Benefits ONE CVS DRIVE, WOONSOCKET RI 02895
Tilak Mandadi officer: EVP, Chief Technology Officer 3600 LAS VEGAS BLVD. SOUTH, LAS VEGAS NV 89109
Sreekanth K Chaguturu officer: EVP and Chief Medical Officer ONE CVS DRIVE, WOONSOCKET RI 02895
Prem S Shah officer: EVP and Co-President of Retail ONE CVS DRIVE, WOONSOCKET RI 02895

CVS Health (CVS Health) Headlines

From GuruFocus

CVS Health to Acquire Signify Health Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 CVS Health Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 CVS Health Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 CVS Health Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

CVS Health Corp Investor Day Transcript

By GuruFocus Research 01-22-2024

Q3 2021 CVS Health Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024